Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (321-330 of 379) with videos related to

Pageof 38
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2009
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 studyAndreas Engert, Volker Diehl, Jeremy Franklin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2022
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL TrialPaul J Bröckelmann, Ina Bühnen, Julia Meissner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphomaCarsten Kobe, Georg Kuhnert, Deniz Kahraman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trialBastian von Tresckow, Annette Plütschow, Michael Fuchs, et al.
Hemasphere|November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study GroupAndreas Engert, Helen Goergen, Jana Markova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2020
Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL TrialConrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, et al.
Neurology|September 29, 2020
Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphomaSabine Seidel, Hendrik Pels, Sabine Schlömer, et al.
Blood|May 31, 2023
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studiesDennis A Eichenauer, Ina Bühnen, Christian Baues, et al.
Leukemia|September 29, 2021
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphomaMaria A Garcia-Marquez, Martin Thelen, Sarah Reinke, et al.
International Journal of Cancer|November 19, 2013
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinomaAchim Rothe, Ron D Jachimowicz, Sven Borchmann, et al.
Pageof 38

Showing results (321-330 of 379) with videos related to

Sort By:
Pageof 38
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2009
Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 studyAndreas Engert, Volker Diehl, Jeremy Franklin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2022
Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL TrialPaul J Bröckelmann, Ina Bühnen, Julia Meissner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphomaCarsten Kobe, Georg Kuhnert, Deniz Kahraman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Dose-intensification in early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD14 trialBastian von Tresckow, Annette Plütschow, Michael Fuchs, et al.
Hemasphere|November 15, 2019
Reduced-Intensity Chemotherapy in Patients With Advanced-Stage Hodgkin Lymphoma: Updated Results of the Open-Label, International, Randomised Phase 3 HD15 Trial by the German Hodgkin Study GroupAndreas Engert, Helen Goergen, Jana Markova, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2020
Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL TrialConrad-Amadeus Voltin, Jasmin Mettler, Lutz van Heek, et al.
Neurology|September 29, 2020
Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphomaSabine Seidel, Hendrik Pels, Sabine Schlömer, et al.
Blood|May 31, 2023
Interim PET-guided treatment for early-stage NLPHL: a subgroup analysis of the randomized GHSG HD16 and HD17 studiesDennis A Eichenauer, Ina Bühnen, Christian Baues, et al.
Leukemia|September 29, 2021
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphomaMaria A Garcia-Marquez, Martin Thelen, Sarah Reinke, et al.
International Journal of Cancer|November 19, 2013
The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinomaAchim Rothe, Ron D Jachimowicz, Sven Borchmann, et al.
Pageof 38